AMZ001 – 変形性関節症治療薬のパイプライン

Report Overview

KEY INSIGHTS

AMZ001 is a new topical gel formulation of diclofenac, developed specifically to treat knee osteoarthritis (OA) pain. With a high-strength concentration of 3.06% diclofenac sodium, AMZ001 stands out in the osteoarthritis medication landscape due to its targeted approach, offering effective localized pain relief with a single daily application (QD). Its targeted design helps reduce systemic exposure and minimizes the adverse effects typically associated with oral non-steroidal anti-inflammatory drugs (NSAIDs).

This drug is developed by Amzell BV, a specialized virtual pharmaceutical development company. Amzell BV focuses on advancing candidate or repurposed drugs and medical devices from the proof-of-concept stage through to registration for commercialization. Founded in 2016 and headquartered in Hoofddorp, Netherlands, Amzell BV is part of the larger Frederik Paulsen business network, which includes various healthcare enterprises, including Ferring Pharmaceuticals.

MARKET POTENTIAL AND POSITIONING

AMZ001 is positioned as a strong competitor in the osteoarthritis treatment market, especially for patients looking for effective pain relief with reduced risk of systemic side effects. The gel’s high-strength formulation and single daily application regimen provide a competitive edge over other topical NSAIDs, which may require more frequent application or have lower active ingredient concentrations.

The topical NSAIDs in osteoarthritis treatment are poised for growth as patients and healthcare providers increasingly seek alternatives to oral therapies, which are associated with a higher risk of GI and cardiovascular adverse effects. AMZ001’s unique formulation could further capture a significant share of this market, particularly among patients who are either intolerant of or wish to avoid oral NSAIDs.

REGIONAL ANALYSIS
Inkwood Research offers an analysis of seven key markets:
• United States
o Osteoarthritis (OA) is the most prevalent form of arthritis in the United States, affecting millions of adults and considerably impacting their quality of life. According to the Centers for Disease Control and Prevention (CDC), over 32.5 million adults in the United States are affected by osteoarthritis.
o The prevalence of osteoarthritis (OA) rises with age, making it especially common among older adults. However, younger individuals can also be affected, particularly if they have had joint injuries or other risk factors such as obesity. Women are more prone to developing OA than men, particularly after the age of 50.
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Table of Contents

TABLE OF CONTENTS
1. INTRODUCTION TO THE REPORT
2. AMZ001 OVERVIEW
2.1. PRODUCT DETAIL
2.2. CLINICAL DEVELOPMENT
2.2.1. CLINICAL STUDIES
2.2.2. CLINICAL TRIALS INFORMATION
2.2.3. SAFETY AND EFFICACY
2.3. PRODUCT PROFILE
3. COMPETITIVE LANDSCAPE
3.1. MARKETED THERAPIES
3.2. LATE-STAGE EMERGING THERAPIES
4. AMZ001 MARKETS ASSESSMENT
4.1. MARKET OUTLOOK OF AMZ001 IN OSTEOARTHRITIS
5. 7 MAJOR MARKET’S ANALYSIS
5.1. MARKET SIZE OF AMZ001 IN THE 7 MAJOR MARKETS FOR OSTEOARTHRITIS
5.2. 7 COUNTRY ANALYSIS
5.2.1. MARKET SIZE OF AMZ001 IN UNITED STATES FOR OSTEOARTHRITIS
5.2.2. MARKET SIZE OF AMZ001 IN GERMANY FOR OSTEOARTHRITIS
5.2.3. MARKET SIZE OF AMZ001 IN FRANCE FOR OSTEOARTHRITIS
5.2.4. MARKET SIZE OF AMZ001 IN ITALY FOR OSTEOARTHRITIS
5.2.5. MARKET SIZE OF AMZ001 IN SPAIN FOR OSTEOARTHRITIS
5.2.6. MARKET SIZE OF AMZ001 IN UNITED KINGDOM FOR OSTEOARTHRITIS
5.2.7. MARKET SIZE OF AMZ001 IN JAPAN FOR OSTEOARTHRITIS
6. SWOT ANALYSIS
7. ANALYST PERSPECTIVE

List of Tables

LIST OF TABLES
TABLE 1: AMZ001, CLINICAL TRIAL DESCRIPTION, 2024
TABLE 2: AMZ001, GENERAL DESCRIPTION
TABLE 3: MARKETED THERAPIES
TABLE 4: EMERGING THERAPIES
TABLE 5: AMZ001 MARKET SIZE IN THE 7 MAJOR MARKETS, IN $ MILLION (2019–2032)
TABLE 6: AMZ001 MARKET SIZE IN UNITED STATES, IN $ MILLION (2019–2032)
TABLE 7: AMZ001 MARKET SIZE IN GERMANY, IN $ MILLION (2019–2032)
TABLE 8: AMZ001 MARKET SIZE IN FRANCE, IN $ MILLION (2019–2032)
TABLE 9: AMZ001 MARKET SIZE IN ITALY, IN $ MILLION (2019–2032)
TABLE 10: AMZ001 MARKET SIZE IN SPAIN, IN $ MILLION (2019–2032)
TABLE 11: AMZ001 MARKET SIZE IN UNITED KINGDOM, IN $ MILLION (2019–2032)
TABLE 12: AMZ001 MARKET SIZE IN JAPAN, IN $ MILLION (2019–2032)

List of Figures

LIST OF FIGURES
FIGURE 1: AMZ001 MARKET SIZE IN THE 7 MAJOR MARKETS, IN $ MILLION (2019–2032)
FIGURE 2: AMZ001 MARKET SIZE IN UNITED STATES, IN $ MILLION (2019–2032)
FIGURE 3: AMZ001 MARKET SIZE IN GERMANY, IN $ MILLION (2019–2032)
FIGURE 4: AMZ001 MARKET SIZE IN FRANCE, IN $ MILLION (2019–2032)
FIGURE 5: AMZ001 MARKET SIZE IN ITALY, IN $ MILLION (2019–2032)
FIGURE 6: AMZ001 MARKET SIZE IN SPAIN, IN $ MILLION (2019–2032)
FIGURE 7: AMZ001 MARKET SIZE IN UNITED KINGDOM, IN $ MILLION (2019–2032)
FIGURE 8: AMZ001 MARKET SIZE IN JAPAN, IN $ MILLION (2019–2032)

Inkwood Researchは広範な市場を対象にし、また主要地域/国別の市場調査レポートで世界中の企業に活用されているインドに本社をおく市場調査会社です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

世界市場レポート

地域別レポート

国別レポート

ご購入に関するご案内

価格・納期について

• 価格
  • 2023年7月より全レポートの価格が値上げされました。弊社ウェブサイトでは旧価格が掲載されているページもございますが、2023年6月以前に出版されたレポートにも値上げが適用されます。予めご了承ください。
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
    • 印刷不可設定のPDFです。
  • コーポレートライセンス
    • 同一企業および関連会社間人数無制限でレポートファイルをご共有可能です。
    • PDF（印刷可能）とExcelをご提供いたします。
• 納期
  • ご注文後3-4営業日以内

• 納品形態
  • Eメール

注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでのご注文をお待ちしております。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

Inkwood Research出版の市場調査レポートに関するご質問やサンプルページのご依頼等はいつでもお気軽にお問合せください。

Inkwood Research 出版レポート一覧